Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 15/20 | 1.00 |
| ▸ | DDO | Q99489 | 5/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9389416 | 0.79 | DAO (0.66) | DAODDO | |
| SCHEMBL22198975 | 0.79 | DAO (0.65) | DAODDOCA12CA9AKR1B1 | |
| SCHEMBL31378942 | 0.79 | DAO (0.65) | DAODDOCA12CA9AKR1B1 | |
| SCHEMBL3362300 | 0.79 | DAO (1.00) | DAODDOCA12CA9HRH4 | |
| SCHEMBL3316092 | 0.79 | DAO (0.65) | DAODDOCA12CA9AKR1B1 | |
| SCHEMBL16767856 | 0.79 | DAO (1.00) | DAODDO | |
| SCHEMBL15690441 | 0.79 | DAO (0.65) | DAODDOCA12CA9HRH4 | |
| SCHEMBL3364081 | 0.79 | DAO (0.65) | DAODDO | |
| SCHEMBL27443353 | 0.78 | DAO (0.64) | DAOCA12CA9AKR1B1HRH4 | |
| SCHEMBL27283387 | 0.77 | DAO (0.62) | DAODDOCA12CA9AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9468669-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-10-18 | — | — | US | disclosed |
| US-9468669-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160228515-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160228515-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-08-11 | — | — | US | disclosed |
| US-9339482-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-05-17 | — | — | US | disclosed |
| US-9339482-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150150836-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2015-06-04 | — | — | US | disclosed |
| US-20150150836-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150836-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | SLC2A4, SLC2A2, SLC2A3 | DAO 3050/4885DDO 2128/4885CA12 434/4885 |
| US-20160228515-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | SLC2A4, SLC2A2, SLC2A3 | DAO 3050/4885DDO 2128/4885CA12 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.